You are using an old and unsupported browser. Most core functionality will not work. Please upgrade to a supported browser - Google Chrome

CICM 2021 ASM: Respiratory
Times are shown in your local time zone (GMT )

CICM 2021

Virtual ASM Scientific Program

Filter & Search
Session Type
Day 1
Day 2
Day 3
Speaker: Ruanne Brell - Senior Legal Advisor – Advocacy, Education and Research Senior Solicitor – Medico-legal Advisory Service. 
To view our Avant Mutual Speaker: Visit the Sponsored Speakers Page.
Welcome to Day 2 of the CICM 2021 ASM.  Our Host for today: Dr Rob Bevan will guide us through the days events.
A number of presentations will be running during the break.  Stay and watch or take time to visit the exhibition zone to support our valued sponsors and exhibitors or pop into one of the networking rooms. 
This session will provide an update regarding asthma prevalence in the community and mortality rates in children over the last 10 years. The session will also highlight some of the outcomes of patients who have been admitted into Paediatric Intensive Care Units for asthma and the risk factors that lead to these presentations. Asthma adherence continues to be an ongoing problem in children with asthma, despite their level of severity and we will highlight some simple strategies to improve adherence. We will be reviewing the concept of asthma remission for children with different levels of asthma severity. Lastly we will be reviewing emerging therapies used in paediatric asthma, with a particular focus on the use of biologics.

A bronchopleural fistula is an unnatural communication between the bronchial tree (at the level of the main stem, lobar or segmental bronchus) and pleural space as evidenced by continued and persistent air leak into the pleural cavity. It is a source of significant morbidity and mortality and can be difficult to manage/treat.  

In this rapid fire up-date we will briefly look at potential aetiologies and the diagnostic evaluation of bronchopleural fistula but spend most time reviewing management strategies. We will evaluate escalating management options for bronchopleural fistulas from chest drains to pneumonectomy and everything in between with particular attention to potential bronchscopic interventions such as occlusive devices and endobronchial stents. 

Take time to visit our exhibition zone and support our much valued sponsors and exhibitors. To access the exhibitors, simply click on sponsors and exhibitors on the left side panel, then select the company you wish to meet with. 
SESSION CHAIR: Dr Lewis Campbell
Session Sponsor: Pfizer
The influence of ethnic background on incidence and outcomes in COVID-19 is an evolving story with strong socio-political as well as clinical repercussions. Definitions and perception of ethnic background is an enormously complex topic which vary greatly within and between countries. Given the importance placed on ethnic identification and the persistent healthcare inequalities experienced by minority ethnic groups in many nations it is important to address these issues in the context of the current pandemic.
To illuminate these issues, we present a summary of analyses describing disparate outcomes between ethnic groups in almost 2000 COVID-19 associated admissions during the first wave to Barts Health NHS Trust. With a catchment of around 2.5 million people living in east London, Barts Health serves one of the most ethnically and economically diverse communities in the UK. In the first wave patients from (South) Asian and Black backgrounds had higher age-adjusted mortality from COVID-19 infection despite controlling for all previously identified confounders and frailty. These patient groups suffered disproportionate rates of premature death from COVID-19 and greater acute disease severity.
Importantly since the first wave of COVID-19 there have been changes in public behaviours, COVID-19 treatments and processes of care. Analysis of patients admitted in the second wave demonstrated that although hospital outcomes and overall mortality were improving, increased risk of death associated with Asian ethnicity persisted. Furthermore, Asian and Black patients continued to have higher rates of admission and acquired more severe disease at a younger age. Comparative analysis of acute hospital admissions over a 6-year period preceding COVID-19 showed an earlier age at presentation and distinct and earlier burden of comorbid disease in patients from minority ethnic groups. Some of these features may explain the adverse outcomes seen in COVID-19 in our community.
As part of the NSW response to COVID-19 Pandemic we explored what was required to quadruple ICU capacity. It involved hospitals identifying surge capacity, ordering of essential equipment and the Intensive Care Operations Team as part of the overall Health response having visibility of all aspects of planning. As expected, true ICU capacity is not dependent so much on the physical ICU bed and ventilators but workforce (skill mix as well as availability), baseline non-COVID ICU activity as well as availability of PPE. Further, the impact of COVID on ICU capacity would not be uniform across the state. Lead by the Agency of Clinical Innovation, in conjunction with the Ministry of Health and the Sax Institute, modelling was developed to demonstrate predicted ICU capacity using ANZICS Adult Patient Database and workforce information in response to different levels of COVID surge as well as staff availability. The proof of concept modelling has far reaching potential for ICU service planning beyond responding to threats such as a pandemic.